Press Releases

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced the appointment by the Board of Directors of Ben-Zion Zilberfarb as a new director of the Company. Dr. Zilberfarb was appointed to...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $60 million of the Company's common stock through February 8, 2009 under...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the second quarter of fiscal year 2007 ended December 30, 2006. Perrigo Company (in thousands, except per share amounts)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2007 on Thursday, Feb. 1, 2007 at approximately 7:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's President and CEO will present at the 25th Annual JPMorgan Healthcare Conference on Thursday, January 11,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Simvastatin Tablets, USP, 5 mg, 10 mg, 20...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Ciclopirox Topical...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U. S. Food & Drug Administration (FDA) has issued an approvable letter for Dexcel Pharma Technologies, Ltd.'s New Drug...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.045 per share, payable on December 19, 2006 to shareholders of record...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) has released the following information regarding its voluntary recall announced early this morning. The voluntary recall was tied to certain lots of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has initiated a voluntary, nationwide product recall to the retail level of certain lots of its store brand Acetaminophen 500...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2007 first quarter that ended September 30, 2006. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2007 on Tuesday, Oct. 31, 2006 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today welcomed Joe Papa as its President and Chief Executive Officer. Mr. Papa succeeds Dave Gibbons who is now the Company's Executive Chairman of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will conduct a brief conference call at 10:00 a.m. (ET) on October 10, 2006 introducing Joe Papa as President and Chief Executive Officer. There will be...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been granted tentative approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market over-the- counter (OTC)...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has elected Joseph C. Papa as its President and Chief Executive Officer effective October 9. Mr. Papa...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Perrigo Israel Pharmaceuticals subsidiary has been granted tentative approval from the U. S. Food and Drug Administration...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on September 19, 2006 to shareholders of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the full year and fourth quarter ended July 1, 2006. Perrigo Company (in thousands, except per share amounts) Fourth...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, InvaGen Pharmaceuticals, Inc., has received tentative approval from the U.S. Food and Drug Administration (FDA) on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2006 on Wednesday, Aug. 9, 2006 at approximately 8:30 a.m. (ET). The Company...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Judy L. Brown has assumed the role of Executive Vice President, Chief Financial Officer and Chief Accounting Officer effective...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Kali Laboratories, Inc., a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), has received...

Since the acquisition of Agis, Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) has pursued opportunities to integrate both businesses and to make them as efficient as possible, while at the same time...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U. S. Food and Drug Administration (FDA) to market over-the-counter (OTC) coated nicotine...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announces its association with Dexcel Pharma Technologies, Ltd.'s new drug application for a generic version of Prilosec OTC®. Under the terms of an...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on June 20, 2006 to shareholders of record on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) invites the public to access a webcast of Chairman, President and CEO, David Gibbons' presentation at the Bank of America 2006 Health Care Conference...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today acknowledges its association with the patent challenge of NASACORT® AQ initiated by Barr Laboratories, Inc. a subsidiary of Barr Pharmaceuticals,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the third quarter of fiscal year 2006 ended March 25, 2006. The acquisition of Agis Industries was completed on March 17,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2006 on Thursday, April 27, 2006 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that its shareholder Rights Agreement expired on April 10, 2006. The Company said there were no plans to renew it. The Perrigo...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market terconazole vaginal...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) invites the public to access a webcast of Chairman, President and CEO, Dave Gibbons' presentation at the Bank of America 2006 Consumer Conference on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Ciclopirox Olamine Cream USP,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Chief Financial Officer Douglas R. Schrank will retire from his post on June 30, 2006. Judy L. Brown, Senior Vice President and...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, through a partnership with InvaGen Pharmaceuticals, it has received tentative approval from the U.S. Food and Drug...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced the appointment by the Board of Directors of Ran Gottfried as a new director of the Company. Mr. Gottfried was appointed to serve for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on March 21, 2006 to shareholders of record...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) nicotine polarcrilex...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the second quarter of fiscal year 2006 ended Dec. 24, 2005. The acquisition of Agis Industries was completed on March 17,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2006 on Thursday, Feb. 2, 2006 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Desoximetasone Gel USP,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on December 20, 2005 to shareholders of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the first quarter of fiscal year 2006 ended Sept. 24, 2005. The acquisition of Agis Industries was completed on March 17,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Perrigo Israel Pharmaceuticals Ltd. (formerly Agis Industries (1983) Ltd.) subsidiary is challenging the patent submitted to...

SCOLR Pharma, Inc. (AMEX: DDD) and Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that they entered into an agreement whereby Perrigo will manufacture and market certain sustained...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2006 on Thursday, Oct. 27, 2005 at approximately 8:30 a.m. (ET). The...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that through a partnership with InvaGen Pharmaceuticals, it has received final approval from the U.S. Food and Drug Administration (FDA) to...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announces the following Webcast: What: Perrigo Analysts' Meeting When: Thursday, September 22, 2005, 9:00 a.m. - Noon (ET) And Friday, September 23,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Famotidine Tablets USP,...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the full year and fourth quarter ended June 25, 2005. The acquisition of Agis Industries was completed on March 17, 2005....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fourth quarter and fiscal year 2005 on Wednesday, Sept. 7, 2005 at approximately 8:30 a.m....

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, through a partnership with InvaGen Pharmaceuticals, it has received tentative approval from the U.S. Food and Drug...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.04 per share, payable on September 20, 2005 to shareholders of record...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market prescription Ibuprofen...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market over-the- counter (OTC)...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has adopted a written trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 to facilitate the repurchase of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the third quarter and nine months of fiscal 2005 ended March 26, 2005. Perrigo Company (in thousands, except per share...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Naproxen Tablets USP, 250...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter on Thursday, May 5, 2005 at approximately 8:30 a.m. (ET). The Company will...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has authorized the repurchase of up to $30 million of the Company's common stock over the next 12 months....

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.04 per share, payable on June 21, 2005 to shareholders of record on...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Agis Industries subsidiary has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market...

The Perrigo Company (NASDAQ: PRGO) today announced the completion of its acquisition of Agis Industries (1983) Ltd., a developer and manufacturer of specialized generic pharmaceuticals and active...

The Perrigo Company (NASDAQ: PRGO) announced today that its shareholders approved the issuance of shares of Perrigo common stock in connection with the November 14, 2004 agreement and plan of...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.04 per share, payable on March 22, 2005 to shareholders of record on February 25,...

The Perrigo Company (NASDAQ: PRGO) today announced results for the second quarter and six months of fiscal 2005 ended Dec. 25, 2004. Perrigo Company (in thousands, except per share amounts) Second...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its second quarter on Tuesday, Feb. 1, 2005 at approximately 8:30 a.m. (ET). The Company will conduct a...

Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceuticals and drug delivery company, and Perrigo Company (NASDAQ: PRGO), the nation's largest manufacturer of...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.04 per share, payable on December 21, 2004 to shareholders of record on November...

The Perrigo Company (NASDAQ: PRGO) today announced results for the first quarter of fiscal 2005 ended Sept. 25, 2004. Perrigo Company (In thousands, except per share amounts) Fiscal 2005 Fiscal...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its first quarter on Tuesday, October 26, 2004 at approximately 8:30 a.m. (ET). The Company will conduct a...

The Perrigo Company (NASDAQ: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) nicotine polacrilex gum and...

The Perrigo Company (NASDAQ: PRGO) today announced results for the full year and fourth quarter ended June 26, 2004. Perrigo Company (in thousands, except per share amounts) Fourth Quarter...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.035 per share, payable on September 21, 2004, to shareholders of record on August...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its fourth quarter and year-end on Tuesday, August 10, 2004 at approximately 8:30 a.m. (ET). The Company...

Today the Perrigo Company (NASDAQ: PRGO) announced that it is negotiating a settlement with the U.S. Federal Trade Commission (FTC) in order to close the FTC's investigation into a 1998 agreement...

The Perrigo Company (NASDAQ: PRGO) announced today that it has entered into a purchase agreement to acquire certain assets of APG, Inc., a privately-owned contract manufacturer and packager of...

The Perrigo Company (NASDAQ: PRGO) said today that it had completed a review of the May 2004 contract between Lannett Company, Inc. (AMEX: LCI) and Jerome Stephens Pharmaceutical, Inc. (JSP). As...

Perrigo Company (NASDAQ: PRGO) said today that Lannett Company, Inc. (AMEX: LCI) announced it has signed a supply agreement with Jerome Stevens Pharmaceuticals, Inc. (JSP) for the exclusive...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.035 per share, payable on June 22, 2004, to shareholders of record on May 28,...

The Perrigo Company (NASDAQ: PRGO) today announced results for the third quarter and nine months of fiscal 2004 ended March 27, 2004. Perrigo Company (in thousands, except per share amounts) Third...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its third quarter on Friday, April 23, 2004 at approximately 8:30 a.m. (ET). The Company will conduct a...

The Perrigo Company (NASDAQ: PRGO) invites the public to access a webcast of the Company's presentation at the Banc of America Securities Consumer Conference on Thursday, April 1 at 10:50 a.m....

The Perrigo Company (NASDAQ: PRGO) today announced it has acquired Peter Black Pharmaceuticals, Ltd. for approximately $13 million in cash. Based in Swadlincote, United Kingdom, privately held...

The Perrigo Company (NASDAQ: PRGO) today announced that it will begin marketing three new products following U.S. Food and Drug Administration (FDA) approvals. More specifically, these new...

The Perrigo Company (NASDAQ: PRGO) announced today that, as Alpharma Inc. reported in its 10-Q, the U.S. Federal Trade Commission is investigating a 1998 agreement between Alpharma and Perrigo....

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors has authorized the repurchase of an additional $20 million of the Company's common stock under its ongoing share...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors declared a quarterly dividend of $.035 per share, payable on December 23, 2003 to shareholders of record on November...

The Perrigo Company (NASDAQ: PRGO) today announced results for the first quarter of fiscal 2004 ended September 27, 2003. Perrigo Company (NASDAQ: PRGO) (In thousands, except per share amounts)...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its first quarter on Friday, October 24, 2003 at approximately 8:30 a.m. ET. The Company will conduct a...

The Perrigo Company (NASDAQ: PRGO) announced today it has signed a licensing agreement with Sierra Medicinals, Inc. to manufacture and market the Dr. Steven Rosenblatt brand dietary supplement,...

Perrigo Company (NASDAQ: PRGO) announced today that Todd Kingma has joined the company as Vice President & General Counsel, replacing Jack Nichols who will be retiring next year after 10 years as...

The Perrigo Company (NASDAQ: PRGO) today announced that its Board of Directors has elected David T. Gibbons, President and Chief Executive Officer, to the additional responsibility of Chairman of...

The Perrigo Company (NASDAQ: PRGO) today announced results for the full year and fourth quarter ended June 28, 2003. Perrigo Company (NASDAQ: PRGO) (in thousands, except per share amounts) Fourth...

Perrigo Company (NASDAQ: PRGO) today announced that it will release financial results for its fourth quarter and fiscal 2003 year end on Monday, August 11, 2003 at approximately 8:30 a.m. EDT. The...